S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
NYSE:CANO

Cano Health (CANO) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$2.00
$9.31
52-Week Range
N/A
Volume
159,142 shs
Average Volume
423,785 shs
Market Capitalization
$12.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.85

Cano Health MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.67 Rating Score
Upside/​Downside
∞ Upside
$1.85 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.22mentions of Cano Health in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$640,233 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.01) to ($29.82) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.37 out of 5 stars

Medical Sector

879th out of 911 stocks

Offices & Clinics Of Medical Doctors Industry

6th out of 7 stocks

CANO stock logo

About Cano Health Stock (NYSE:CANO)

Cano Health, Inc. provides primary care medical services to its members in the United States and Puerto Rico. It owns and operates medical centers enabled by CanoPanorama, a proprietary population health management technology-powered platform that provides the healthcare providers at its medical centers with a 360-degree view of their members with actionable insights to improve care decisions and member engagement. The company also operates pharmacies, as well as provides dental services in its medical centers. Cano Health, Inc. was founded in 2009 and is headquartered in Miami, Florida.

CANO Stock News Headlines

Cano Health, Inc. (CANOQ)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
American League East Preview Capsules
Firm Retention Summary: Cano Health
See More Headlines
Receive CANO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cano Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/19/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Offices & clinics of medical doctors
Sub-Industry
N/A
Fax
N/A
Employees
4,365
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.85
High Stock Price Target
$3.75
Low Stock Price Target
$0.80
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
3 Analysts

Profitability

Net Income
$-207,270,000.00
Pretax Margin
-36.27%

Debt

Sales & Book Value

Annual Sales
$2.74 billion
Book Value
$100.28 per share

Miscellaneous

Free Float
4,653,000
Market Cap
$12.39 million
Optionable
Optionable
Beta
0.05
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

CANO Stock Analysis - Frequently Asked Questions

Should I buy or sell Cano Health stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cano Health in the last twelve months. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" CANO shares.
View CANO analyst ratings
or view top-rated stocks.

What is Cano Health's stock price target for 2024?

3 analysts have issued 1 year price objectives for Cano Health's shares. Their CANO share price targets range from $0.80 to $3.75. On average, they anticipate the company's share price to reach $1.85 in the next twelve months.
View analysts price targets for CANO
or view top-rated stocks among Wall Street analysts.

This page (NYSE:CANO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners